Literature DB >> 23175270

A randomized trial comparing conventional cytology to liquid-based cytology and computer assistance.

Stefanie J Klug1, Klaus J Neis, Werner Harlfinger, Armin Malter, Jochem König, Sibylle Spieth, Friederike Brinkmann-Smetanay, Friedrich Kommoss, Veronika Weyer, Hans Ikenberg.   

Abstract

Liquid-based cytology (LBC) has replaced conventional cytology (CC) for cervical cancer screening in some countries. However, it remains unclear whether LBC is superior to CC. A randomized controlled trial was conducted between August 2007 and March 2009 in Germany to compare LBC, alone and in combination with computer-assisted imaging technology (CAS), to CC in the detection of histologically confirmed cervical intraepithelial neoplasia (CIN). The main outcome measures were detection rates, relative sensitivities, positive predictive values (PPVs) and relative PPVs comparing LBC without and with CAS to CC. Primary histological outcome was CIN2 or higher. Included were 20,627 women participating in opportunistic cervical cancer screening at 20 gynecologic practices. The practices were randomized weekly to use LBC (n = 11,331) or CC (n = 9,296). Patients with positive findings were invited to expert colposcopy. The relative sensitivity of LBC versus CC using the CIN2+ cut-off was 2.74 (95% confidence interval [CI] 1.66-4.53). The relative sensitivity of LBC/CAS versus CC for CIN2+ was 3.17 (95% CI 1.94-5.19). The PPV of LBC and CC for CIN2+ was 48% and 38%, respectively. The PPV ratio did not differ significantly from unity. Differences between LBC and CC were smaller in some sensitivity and subgroup analyses; however, relative sensitivity of LBC remained increased. LBC without and with CAS compared with CC under the field conditions of an opportunistic screening system had a significantly higher sensitivity for the detection of CIN without deterioration of PPVs. Additional use of CAS did not further improve sensitivity of LBC. © 2012 Wiley Periodicals, Inc.
Copyright © 2012 UICC.

Entities:  

Mesh:

Year:  2012        PMID: 23175270     DOI: 10.1002/ijc.27955

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

Review 1.  [Who performs gynecological cytology and how?].

Authors:  D Schmidt; H H Neumann
Journal:  Pathologe       Date:  2015-11       Impact factor: 1.011

Review 2.  Artificial Intelligence in Pathology: From Prototype to Product.

Authors:  André Homeyer; Johannes Lotz; Lars Ole Schwen; Nick Weiss; Daniel Romberg; Henning Höfener; Norman Zerbe; Peter Hufnagl
Journal:  J Pathol Inform       Date:  2021-03-22

3.  Cervical cancer incidence after normal cytological sample in routine screening using SurePath, ThinPrep, and conventional cytology: population based study.

Authors:  Kirsten Rozemeijer; Steffie K Naber; Corine Penning; Lucy I H Overbeek; Caspar W N Looman; Inge M C M de Kok; Suzette M Matthijsse; Matejka Rebolj; Folkert J van Kemenade; Marjolein van Ballegooijen
Journal:  BMJ       Date:  2017-02-14

4.  Liquid-based cytology for the detection of cervical intraepithelial lesions in Jimma town, Ethiopia.

Authors:  Getnet Tesfaw; Yesuf Ahmed; Lealem Gedefaw; Lamessa Dube; Samson Godu; Kirubel Eshetu; Mesfin Nigussie; Haftamu Hailekiros; Moses Joloba; Gelila Goba; Alemseged Abdissa
Journal:  BMC Cancer       Date:  2020-07-29       Impact factor: 4.430

5.  Cost-Effectiveness and Cost-Benefit of Cervical Cancer Screening with Liquid Based Cytology Compared with Conventional Cytology in Germany.

Authors:  Stephanie F Armstrong; Julian F Guest
Journal:  Clinicoecon Outcomes Res       Date:  2020-03-17

6.  Cervical histology after routine ThinPrep or SurePath liquid-based cytology and computer-assisted reading in Denmark.

Authors:  Matejka Rebolj; Johanne Rask; Marjolein van Ballegooijen; Benny Kirschner; Kirsten Rozemeijer; Jesper Bonde; Carsten Rygaard; Elsebeth Lynge
Journal:  Br J Cancer       Date:  2015-10-08       Impact factor: 7.640

7.  Comparing SurePath, ThinPrep, and conventional cytology as primary test method: SurePath is associated with increased CIN II+ detection rates.

Authors:  Kirsten Rozemeijer; Corine Penning; Albert G Siebers; Steffie K Naber; Suzette M Matthijsse; Marjolein van Ballegooijen; Folkert J van Kemenade; Inge M C M de Kok
Journal:  Cancer Causes Control       Date:  2015-10-12       Impact factor: 2.506

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.